Bulevirtide (Hepcludex®). HTA ID: 22067

Assessment Status Full HTA submission received from Applicant
HTA ID 22067
Drug Bulevirtide
Brand Hepcludex®
Indication Chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease.
Assessment Process
Rapid review commissioned 06/10/2022
Rapid review completed 10/11/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bulevirtide compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/11/2022
Pre-submission consultation with Applicant 10/01/2023
Full submission received from Applicant 06/09/2023